Addiction To The Injectable Form Of Buprenorphine
-- Buprenex
Injectable-buprenex addiction is a problem that is on the rise in many parts of Europe as well as the rest of the world. Although the figures of injectable-buprenex addiction in the US are not available, and there is surprisingly little data available about the diversion or abuse of the injectable-buprenex product, chances are that some people at least are struggling with an addiction to the injectable-buprenex form of buprenorphine.
Buprenorphine is a pain medication that is a synthetic opiate. It is similar, in chemical structure, to the other more commonly known opiate drugs like morphine, heroin and codeine etc. Buprenorphine is pharmacologically classified as agonist-antagonist to opioids. So, it has what is called a ceiling effect. It has the same effect on the body of the user, as the other opiates, creating extreme relaxation and producing a high state of euphoria. The euphoric state that injectable-buprenex produces, is considerably less high than those of cocaine or heroine, and this possible means that it may be slightly easier to stop taking the injectable-buprenex.
Abuse of buprenorphine, especially in the injectable-buprenex form, is present and recorded in countries of Europe and the rest of the world. Very little abuse or diversion of injectable buprenorphine has been reported in the US since as early as 1985. However, this does not mean that the problem of injectable-buprenex addiction is absent. In the past, other drugs like pentazocine has failed to be identified as the subject of abuse for as long as they had been available solely as an injectable. However, these drugs quickly became subject to abuse, and mass diversions of the drugs were reported, as soon as the formulations were changed to tablets or nasal sprays. The FDA has approved tablet forms of buprenorphine, for sublingual use, to be prescribed for the treatment addiction. As a result, the DEA has designated buprenorphine as a Schedule III controlled substance. This makes the restrictions on the injectable-buprenex form, as well as others, higher.
Buprenorphine in any form, even the low dosage injectable-buprenex can cause death if an overdose occurs. This danger is higher for people who are struggling with injectable-buprenex addiction, since they often mix other substances for a better high. If injectable-buprenex is injected with a tranquilizer, the dangers of an overdose are increased manifold. Buprenorphine also causes dependence. As a result, any attempt to stop using the medication too quickly, or abruptly, can cause fairly severe withdrawal symptoms. The beginning of detox and treatment for injectable-buprenex addiction also causes withdrawal symptoms as a result of this very physical dependence.
The injectable buprenorphine dosage form, injectable-buprenex, was approved for marketing in 1985. However, unlike other forms of buprenorphine, injectable-buprenex is not approved for addiction treatment use. Hence, Buprenex cannot be prescribed by any physician, for the treatment of addiction to opiates under DATA. This injectable-buprenex form of Buprenorphine cannot and must not be used for occasional or as needed purposes. Unless taken under the strict supervision of a qualified medical practitioner, the dependence and tolerance caused by this dug can easily lead to injectable-buprenex addiction. While stopping the medication, equal care must be exercised. Don’t stop taking injectable-buprenex without doctor’s supervision, to handle and minimize the withdrawal. Chances are that your doctor would choose a tapering rather than a sudden stoppage. They would prescribe slightly smaller and smaller doses, over a period of time, gradually reducing the dose to acclimatize your body and minimizing or avoiding the withdrawal symptoms associated with injectable-buprenex addiction.
Injectable-buprenex addiction is a problem that is on the rise in many parts of Europe as well as the rest of the world. Although the figures of injectable-buprenex addiction in the US are not available, and there is surprisingly little data available about the diversion or abuse of the injectable-buprenex product, chances are that some people at least are struggling with an addiction to the injectable-buprenex form of buprenorphine.
Buprenorphine is a pain medication that is a synthetic opiate. It is similar, in chemical structure, to the other more commonly known opiate drugs like morphine, heroin and codeine etc. Buprenorphine is pharmacologically classified as agonist-antagonist to opioids. So, it has what is called a ceiling effect. It has the same effect on the body of the user, as the other opiates, creating extreme relaxation and producing a high state of euphoria. The euphoric state that injectable-buprenex produces, is considerably less high than those of cocaine or heroine, and this possible means that it may be slightly easier to stop taking the injectable-buprenex.
Abuse of buprenorphine, especially in the injectable-buprenex form, is present and recorded in countries of Europe and the rest of the world. Very little abuse or diversion of injectable buprenorphine has been reported in the US since as early as 1985. However, this does not mean that the problem of injectable-buprenex addiction is absent. In the past, other drugs like pentazocine has failed to be identified as the subject of abuse for as long as they had been available solely as an injectable. However, these drugs quickly became subject to abuse, and mass diversions of the drugs were reported, as soon as the formulations were changed to tablets or nasal sprays. The FDA has approved tablet forms of buprenorphine, for sublingual use, to be prescribed for the treatment addiction. As a result, the DEA has designated buprenorphine as a Schedule III controlled substance. This makes the restrictions on the injectable-buprenex form, as well as others, higher.
Buprenorphine in any form, even the low dosage injectable-buprenex can cause death if an overdose occurs. This danger is higher for people who are struggling with injectable-buprenex addiction, since they often mix other substances for a better high. If injectable-buprenex is injected with a tranquilizer, the dangers of an overdose are increased manifold. Buprenorphine also causes dependence. As a result, any attempt to stop using the medication too quickly, or abruptly, can cause fairly severe withdrawal symptoms. The beginning of detox and treatment for injectable-buprenex addiction also causes withdrawal symptoms as a result of this very physical dependence.
The injectable buprenorphine dosage form, injectable-buprenex, was approved for marketing in 1985. However, unlike other forms of buprenorphine, injectable-buprenex is not approved for addiction treatment use. Hence, Buprenex cannot be prescribed by any physician, for the treatment of addiction to opiates under DATA. This injectable-buprenex form of Buprenorphine cannot and must not be used for occasional or as needed purposes. Unless taken under the strict supervision of a qualified medical practitioner, the dependence and tolerance caused by this dug can easily lead to injectable-buprenex addiction. While stopping the medication, equal care must be exercised. Don’t stop taking injectable-buprenex without doctor’s supervision, to handle and minimize the withdrawal. Chances are that your doctor would choose a tapering rather than a sudden stoppage. They would prescribe slightly smaller and smaller doses, over a period of time, gradually reducing the dose to acclimatize your body and minimizing or avoiding the withdrawal symptoms associated with injectable-buprenex addiction.
For additional information on addiction treatment or the drug
Suboxone,
For additional information on addiction treatment or the drug
Suboxone,
Call now 1-888-Suboxone or 1-888-782-6966
E-mail: Support@SoftLandingRecovery.com>
Content provided by the Editorial Board.
This article is written by a freelance writer. It might not reflect the views and opinions of Soft Landing ltd. or its staff but has been placed here
so that our visitors may get an idea of how others think of the topic.
Information on this page last updated on 09/17/2007